Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Investigators.
Szarek M, et al. Among authors: baccara dinet m.
Eur Heart J. 2020 Nov 21;41(44):4245-4255. doi: 10.1093/eurheartj/ehaa649.
Eur Heart J. 2020.
PMID: 33051646
Free PMC article.
Clinical Trial.